Ticker
ABLI.ST

Price
0.31
Stock movement down
-0.01 (-3.98%)
Company name
Abliva AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
331.15M
Ent value
279.55M
Price/Sales
4191.77
Price/Book
1.82
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-41.13%
3 year return
-36.42%
5 year return
-38.24%
10 year return
-34.63%
Last updated: 2023-02-01

DIVIDENDS

ABLI.ST does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4191.77
Price to Book1.82
EV to Sales3538.62

FINANCIALS

Per share

Loading...
Per share data
Current share count1.06B
EPS (TTM)-0.16
FCF per share (TTM)-0.31

Income statement

Loading...
Income statement data
Revenue (TTM)79.00K
Gross profit (TTM)0.00
Operating income (TTM)-102.23M
Net income (TTM)-104.56M
EPS (TTM)-0.16
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-129410.13%
Profit margin (TTM)-132349.37%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash73.44M
Net receivables94.58M
Total current assets169.15M
Goodwill0.00
Intangible assets20.47M
Property, plant and equipment0.00
Total assets203.67M
Accounts payable15.52M
Short/Current long term debt0.00
Total current liabilities21.22M
Total liabilities21.84M
Shareholder's equity181.83M
Net tangible assets161.40M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-193.66M
Capital expenditures (TTM)885.00K
Free cash flow (TTM)-194.53M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-57.50%
Return on Assets-51.34%
Return on Invested Capital-57.50%
Cash Return on Invested Capital-106.98%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.33
Daily high0.34
Daily low0.31
Daily Volume8.93M
All-time high80.50
1y analyst estimate1.00
Beta0.81
EPS (TTM)-0.16
Dividend per share-
Ex-div date-
Next earnings date24 Feb 2023

Downside potential

Loading...
Downside potential data
ABLI.STS&P500
Current price drop from All-time high-99.61%-14.91%
Highest price drop-99.80%-56.47%
Date of highest drop28 Dec 20229 Mar 2009
Avg drop from high-73.46%-11.49%
Avg time to new high78 days13 days
Max time to new high2139 days1805 days
COMPANY DETAILS
ABLI.ST (Abliva AB) company logo
Marketcap
331.15M
Marketcap category
Small-cap
Description
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Employees
8
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found